Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 1, 2025BJU International

Oncological safety of testosterone replacement therapy in men with localised prostate cancer: a systematic review of observational studies

View Full Paper
Ask AI
Bookmark
Share

Authors

JSJordan SantucciPSPeter StapletonMPMarlon Perera

Discussion

Loading...

Member takes

Overview

Systematic review reveals potential oncological safety of testosterone replacement therapy in men with localized prostate cancer, suggesting careful monitoring is crucial.

Key Points

  • Retrospective evidence suggests testosterone replacement therapy is cautiously safe in low–intermediate-risk prostate cancer.
  • Biochemical recurrence rates in men with prostate cancer receiving TRT ranged from 0% to 7% post-radical prostatectomy.
  • Active surveillance studies indicate no significant progression difference compared to non-exposed controls over 70 months.
  • Current limitations include lack of long-term, prospective studies to better assess the oncological safety of TRT.

Cite This Study

Santucci et al. (2025) studied this question.

synapsesocial.com/papers/689a0c6be6551bb0af8cfd5fhttps://doi.org/10.1111/bju.16870
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Testosterone Replacement Therapy in Hypogonadal Men with a Prostate Cancer Diagnosis: A British Society for Sexual Medicine Consensus Statement2025
  2. 2How does Testosterone Therapy Impact Quality of Life and Cancer Recurrence Rates in High-Risk Prostate Cancer Survivors? : A Systematic Review2025
  3. 3Testosterone Treatment in Prostate Cancer Survivors With Hypogonadism2026
  4. 4Association Between Testosterone Replacement Therapy and Prostatic Disorders in Elderly Hypogonadal Men2025
  5. 5Impact of Testosterone Recovery on Oncologic Outcomes in High‐Risk, Localized Prostate Cancer2025